Glioblastomas (GBMs), the most common and malignant brain tumors, are highly resistant to current therapies. The failure of targeted therapies against aberrantly activated oncogenic signaling, such as that of the EGFR-PI3K/Akt pathway, underscores the urgent need to understand alternative downstream pathways and to identify new molecular targets for the development of more effective treatments for gliomas. Here, we report that EGFRvIII (DEGFR/de2-7EGFR), a constitutively active EGFR mutant that is frequently co-overexpressed with EGFR in clinical GBM tumors, promotes glioma growth and invasion through protein kinase A (PKA)-dependent phosphorylation of Dock180, a bipartite guanine nucleotide exchange factor (GEF) for Rac1. We demonstrate that EGFRvIII induces serine phosphorylation of Dock180, stimulates Rac1 activation and glioma cell migration. Treatments of glioma cells using the PKA inhibitors H-89 and KT5720, overexpression of a PKA inhibitor (PKI), and in vitro PKA kinase assays show that EGFRvIII induction of serine phosphorylation of Dock180 is PKA-dependent. Significantly, PKA induces phosphorylation of Dock180 at amino acid residue S1250 that resides within its Rac1-activating DHR-2 domain. Expression of the Dock180 S1250L mutant, but not wild type Dock180 WT , protein in EGFRvIII-expressing glioma cells inhibited receptor-stimulated cell proliferation, survival, migration in vitro and glioma tumor growth and invasion in vivo. Together, our findings describe a novel mechanism by which EGFRvIII drives glioma tumorigenesis and invasion through PKA-dependent phosphorylation of Dock180, thereby suggesting that targeting EGFRvIII-PKA-Dock180-Rac1 signaling axis could provide a novel pathway to develop potential therapeutic strategies for malignant gliomas.
INTRODUCTION
Glioblastomas are the most common and malignant tumors of the central nervous system whose poor overall survival of 12-14 months upon diagnosis are due to a limited effectiveness of available therapies. 1, 2 Recent genomic analysis validated and extended previous findings that genetic alterations such as EGFR gene amplification and mutation are major drivers promoting glioma progression and malignancy. 3, 4 It is also known that amplification of the EGFR gene is often associated with a specific EGFR mutation that lacks exons 2-7 (EGFRvIII/DEGFR/del2-7EGFR), leading to constitutively active oncogenic signaling that correlates with worse prognosis. 1, 4 EGFRvIII enhances glioblastoma tumorigenicity in vivo 5 and promotes glioma cell motility in vitro, 6 primarily through PI3K/Akt signaling. However, the failure of treatments using inhibitors of EGFR or PI3K/Akt to alter the prognosis of these deadly brain gliomas underscores the necessity of identifying additional molecular targets that can be exploited for the development of more effective therapeutic interventions. 4, 7 We have previously reported that dedicator of cytokinesis 1 (Dock1 or Dock180), a guanine nucleotide exchange factor (GEF) that activates Rac1 and regulates cell motility, survival and proliferation, 8 has an important role in glioma cell migration and invasion. 9 By binding to its bipartite partner, engulfment and cell motility protein 1 (ELMO1), Dock180 accelerates nucleotide exchange on Rac1 through its Dock-homology region-2 (DHR-2) domain, activating Rac1 signaling. The DHR-1 domain of Dock180 interacts with phosphatidyl-inositol (3,4,5)P 3 (PIP 3 ) and, subsequently promotes translocation of Dock180 to the cell membrane. 10 Based on genetic evidence that Dock180 mediates PDGFR-and EGFR-mediated cell migration in Drosophila, 11 we proposed and demonstrated that the phosphorylation of Dock180 by Src or Src family kinases at two distinct tyrosine residues of Dock180 mediates EGFRvIII-and PDGFRa-driven glioma tumorigenesis and invasion. 12, 13 Moreover, a previous study reported that Dock180 is also phosphorylated at its serine/ threonine residues by activated integrin signaling in fibroblasts, 14 although the biological consequences of this have not been established. As serine/threonine phosphorylation is important in modulating the biological functions of various proteins 15 including GEFs, 8, 16, 17 we examined whether serine phosphorylation of Dock180 has a role in EGFRvIII-promoted glioblastoma tumorigenesis and invasion. Here, we report that EGFRvIII induces serine phosphorylation at serine residue 1250 (S1250) of Dock180 (p-Dock180 invasion in vitro and in vivo. We also found that the EGFRvIII-induced p-Dock180 S1250 is dependent on protein kinase A (PKA) activity and exposure to PKA-specific inhibitors attenuated EGFRvIII-stimulated p-Dock180 S1250 , Rac1 activity, glioma cell migration and proliferation. Our results identify a novel signaling cascade by which EGFRvIII activates Rac1 through PKA-dependent phosphorylation of Dock180 S1250 , thereby promoting glioblastoma tumorigenesis and invasion.
RESULTS

EGFRvIII induces serine phosphorylation of Dock180 in glioma cells
While integrin signaling has previously been shown to induce serine/threonine phosphorylation of Dock180, the biological significance of this was not investigated.
14 Thus, we first sought to determine whether constitutively active EGFRvIII also induces serine phosphorylation (p-S) of Dock180 in human glioma cells. Using an immunoprecipitation (IP) assay to pull down endogenous Dock180 followed by immunoblotting (IB) using a pan anti-p-S antibody, we found that EGFRvIII promoted p-S of Dock180, Rac1 activity and cell migration in SNB19 and LN444 glioma cells that stably expressed EGFRvIII (SNB19/EGFRvIII and LN444/EGFRvIII), but not in control SNB19 and LN444 cells expressing GFP (SNB19/GFP and LN444/GFP) (Figures 1a and b) . To verify the induction of p-S of Dock180 by EGFRvIII, serumstarved SNB19/EGFRvIII and LN444/EGFRvIII cells were treated with or without 10 mM Erlotinib, a specific inhibitor of EGFR 18 for 1 h. As shown in Figures 1a and b , compared with controls, treatment of EGFRvIII-expressing glioma cells with Erlotinib inhibited the induction of p-S of Dock180, Rac1 activity and cell migration, suggesting that EGFRvIII stimulation enhances these biological activities.
PKA is important for EGFRvIII-stimulated serine phosphorylation of Dock180 Next, we sought to determine which kinase might induce serine phosphorylation of Dock180 protein. Using computational approaches (http://scansite.mit.edu and the NetPhosK 1.0 server http://www.cbs.dtu.dk/services/NetPhosK/), we found several serine/threonine kinase candidates that could phosphorylate Dock180 at serine and threonine residues. To determine which among these serine/threonine kinases was responsible for EGFRvIII-induced p-S of Dock180, SNB19/EGFRvIII cells were treated with or without 10 mM GF109203X (an inhibitor of protein kinase C), 20 mM Roscovitine (an inhibitor of cyclin-dependent kinase, Cdk 5 kinase), 50 mM KN-93 (an inhibitor of calmodulindependent kinase 2), 50 mM PD-98059 (an inhibitor of MEK) and 20 mM H-89 (an inhibitor of PKA). As shown in Figure 2a , treatment with H-89 significantly inhibited EGFRvIII-induced p-S of Dock180 compared with the control. In contrast, treatments with inhibitors of the other candidate kinases showed minimal or no effects on the induction of p-S of Dock180 in glioma cells. To further determine whether PKA is the kinase that primarily mediates EGFRvIII stimulation of p-S of Dock180, we treated SNB19/parental, SNB19/EGFRvIII, LN444/parental and LN444/EGFRvIII cells with or without PKA inhibitors H-89 or KT5720. 19, 20 Compared with the control, treatments with both PKA inhibitors markedly attenuated EGFRvIII stimulation of p-S of Dock180, p-Erk1/2, p-Akt, Rac1 activity and cell migration as well as cell proliferation (Figures 2b-e, respectively). Consistent with these data, ectopic expression of a PKA inhibitor (PKI) 21 also reduced EGFRvIII-promoted p-S of Dock180, p-Erk1/2, p-Akt, Rac1 activity, cell migration and cell proliferation of SNB19 and LN444 glioma cells (Figures 2f and g and data not shown). Taken together, these results indicate that PKA is important for EGFRvIII stimulation of p-S of Dock180, p-Erk1/2, p-Akt, Rac1 activity, cell migration, and cell proliferation of glioma cells.
PKA-dependent serine phosphorylation of Dock180 is important for cell migration of primary GBM cells with EGFRvIII overexpression We next determined whether PKA also induces p-S of Dock180, Rac1 activity and cell migration in short-term cultured primary human GBM cells that retain the overexpression of endogenous EGFRvIII that was present in the clinical glioma tumor tissues from which they were derived. 22, 23 To this end, we examined two GBM cell cultures, GBM6 and GBM39. As shown in Figure 3a , in both GBM6 and GBM39 cells that displayed endogenous EGFRvIII overexpression, strong p-S of Dock180 and Rac1 activity was apparent. Treatment of GBM6 and GBM39 cells with the EGFR inhibitor Erlotinib, or PKA inhibitors H-89 and KT5720, markedly reduced EGFRvIII-induced p-S of Dock180, p-Akt, p-Erk1/2, Rac1 activity and cell migration compared with GBM cells treated with vehicle controls (Figures 3a and b) . These results recapitulated our in vitro observations using SNB19 and LN444 cells, further suggesting that PKA-induced p-S of Dock180 is critical for EGFRvIII-stimulated p-Akt, p-Erk1/2, Rac1 activity and cell migration in glioma cells. the DHR-1 domain, between residues 422 to 602, and the N-terminal segment after residue 1111 including the DHR-2 region), and wild type Dock180 (Dock180 WT , Figure 4a ) and expressed each of them separately with or without EGFRvIII in HEK293T cells. As shown in Figure 4b , co-expression of EGFRvIII with WT Dock180 induced the p-S of Dock180 whereas the p-S of Dock180 was significantly diminished when EGFRvIII was coexpressed with the Del-1 or Del-2 mutants (Figure 4b ). This suggested that a major p-S site(s) is located in the region between residues 1111 and 1636 (Figure 4a ). Consequently, we analyzed the protein sequence of Dock180 and found three serine residues, S1198, S1250 and S1627 within this region. Interestingly, by searching online available databases, we found that the S1250 residue of Dock180 was mutated to L1250 in a clinical glioblastoma sample from a patient after treatment with temozolomide (TCGA_GBM_Level3_All_Somatic_Mutations, TCGA portal, https://tcga-data.nci.nih.gov). Thus, we next individually coexpressed three Flag-tagged Dock180 mutants, Dock180 S1250L , Dock180 S1198L and Dock180 S1627L , and Dock180 WT individually with EGFRvIII in HEK293T cells. We found that the cells expressing the Dock180 S1250L mutant showed markedly decreased EGFRvIIIinduced p-S of Dock180, whereas no reduction of p-S of Dock180 S1198L or p-S of Dock180 S1627L was seen (Figure 4c ), suggesting that it is the S1250, but not S1198 and S1627, serine residue that is phosphorylated by EGFRvIII stimulation. To determine whether PKA can directly phosphorylate Dock180 at S1250, we performed in vitro p-S assays by incubating purified recombinant (His) 6 -Dock180
WT or (His) 6 -Dock180 S1250L proteins with or without an active recombinant PKA, followed by IB using the pan anti-p-S antibody. As shown in Figure 4d , recombinant PKA effectively induced p-S of Dock180
WT in vitro, whereas the corresponding p-S level of Dock180 S1250L was significantly reduced compared with that of Dock180
WT . Next, we evaluated the impact of PKA-induced p-S of Dock180 on Dock180's interaction with Rac1 using an in vitro reconstitution assay. In this assay, we also included a control Dock180 ISP , a mutant of Dock180 in which the sequence Ile-Ser-Pro has been mutated to Ala-Ala-Ala at amino acids (AA) 1487-1489 in the Rac1 activation domain, resulting in loss of Dock180 ability to interact with and activate Rac1. 24 When Dock180 WT , Dock180 S1250L or Dock180 ISP that had been immunoprecipitated from HEK293T were separately incubated with an active recombinant PKA, high levels of p-S of Dock180 were detected in Dock180 WT , but not in p-SDock180 S1250L proteins (Figure 4e ). This was accompanied with an increase in the association of Dock180 WT , but not Dock180 S1250L , with Rac1 ( Figure 4e ). Moreover, although p-SDock180 ISP was also detected at similar levels compared with that of p-S-Dock180 WT , consistent with previous reports, 24 p-SDock180
ISP failed to interact with Rac1 ( Figure 4e ). Lastly, we compared AA sequences surrounding the S1250 residue in Dock180 from various species as well as with Dock2 and Dock5, two closely related members of the Dock family. We found that S1250 and most of its surrounding AA residues are highly conserved among these proteins (Figure 2f ). Taken together, these results indicate that S1250 is a major p-S site of the Dock180 protein that is phosphorylated by PKA in glioma cells expressing the constitutively active EGFRvIII.
p-S of Dock180
S1250 is important for EGFRvIII-mediated glioma cell proliferation, survival and migration in vitro To determine the impact of PKA-induced p-S of Dock180 S1250 on EGFRvIII-stimulated glioma cellular signaling, cell growth and invasion, we expressed Dock180 WT or Dock180 S1250L using a lentiviral vector in SNB19/EGFRvIII cells. As shown in Figure 5a , when compared with the vector control, expression of Dock180 WT had a minimal impact on EGFRvIII-stimulated p-Akt, p-Erk1/2 and Rac1 activity, whereas expression of Dock180 S1250L attenuated EGFRvIII stimulation of p-Erk1/2 and Rac1 activity but had no effect on p-Akt. Consistent with this, exogenous Dock180
WT expression in SNB19 glioma cells had no appreciable effects on EGFRvIIIstimulated in vitro cell migration, proliferation and survival when compared with the control. In contrast, exogenous expression of the mutant Dock180 S1250L markedly inhibited EGFRvIII-stimulated cell migration, proliferation and survival (Figures 5b-d) . These data suggest that p-S-Dock180 S1250 is important for EGFRvIII-driven stimulation of p-Erk1/2, Rac1 activity, cell migration, proliferation and survival in vitro.
EGFRvIII-stimulated phosphorylation of Dock180 S1250 is required for glioma cell growth and invasion in vivo To further demonstrate the importance of p-S of Dock180 S1250 in EGFRvIII-promoted glioma tumorigenesis and invasion in vivo, we separately implanted SNB19 cells expressing EGFRvIII/Dock180 WT , EGFRvIII/Dock180 S1250L or control EGFRvIII/vector into the brains of mice. As shown in Figure 6A , mice that received SNB19/EGFRvIII/ vector or SNB19/EGFRvIII/Dock180
WT cells developed similarly large and highly invasive gliomas at 60 days post-injection ( Figure 6A, panels a, d compared with b, e, Figures 6B and C) . In contrast, mice that received SNB19/EGFRvIII/Dock180 S1250L cells developed tumors with much smaller volumes and markedly Figures 6B and C) . In addition, expression of Dock180 WT had no significant effect on glioma cell proliferation and survival in the brain ( Figure 6A , comparison of panels h, k with g, j, Figures 6D and E) . In contrast, the expression of Dock180 S1250L significantly suppressed EGFRvIII-stimulated glioma cell proliferation and survival in vivo as compared with SNB19/EGFRvIII/vector or SNB19/EGFRvIII/Dock180 WT tumors ( Figure 6A , comparison of panels i, l with g, j, h and k, Figures 6D and E) . These data suggest that EGFRvIII-induced p-Dock180 S1250 is important for EGFRvIIIpromoted glioma tumor growth, survival and invasion in vivo, and that Dock180 S1250L may act in a dominant negative fashion to inhibit EGFRvIII-driven glioma tumorigenicity and invasion.
DISCUSSION
In the present study, we report that PKA-dependent phosphorylation of serine (p-S) residue 1250 of Dock180 (p-Dock180 S1250 ) is 6 -Dock180 S1250L protein was incubated with or without PKA followed by IP and IB. The purified proteins were also visualized by Comassie brilliant blue staining. IBs for Flag-Dock10 were used as a loading control. (e) PKA-dependent p-S of Dock180 at S1250 enhances association of Dock180 with Rac1. Various Flag-tagged Dock180 proteins were immunoprecipated from HEK293T cells, and then incubated with GFP-Rac1-expressed HEK293T cell lysates in the presence of 10 mM EDTA followed by IP and IB. IBs for Rac1, PKA and b-actin were used as loading controls. (f ) S1250 is conserved in Dock180 of various species and in Dock protein family. Black, conserved AA; Red, non-conserved AA; Blue, conserved serine residues. In b to e, a pan anti-phospho-serine antibody was used to detect p-S-Dock180. Data in b to e are representative of three independent experiments with similar results.
important for tumor growth and invasion of glioblastomas that overexpress EGFRvIII. In glioma cells, EGFRvIII induces p-S of Dock180, which results in glioma cell migration and proliferation both in vitro and in vivo. PKA, but not other AGC protein serine/ threonine kinases, 15 mediates EGFRvIII-stimulated p-S of Dock180, Rac1 activation and cellular behavior. We further identified serine residue 1250 of Dock180 located in the DHR-2 domain that Rac1 binds to, as a major p-S site of PKA activity in EGFRvIII-stimulated glioma cells. Abrogation of PKA-dependent p-S of Dock180 S1250 , by exogenous expression of a Dock180 S1250L mutant but not Dock180
WT , markedly suppressed EGFRvIII-promoted glioma growth and invasion in the brains of animals. Taken together, our data suggest that PKA activation of p-Dock180 S1250 -Rac1 signaling has a critical role in EGFRvIII-driven glioblastoma tumorigenesis.
Similar to other kinases in the AGC protein kinase family, 15 PKA has been implicated in modulating cell growth and motility through phosphorylation of GEFs for Rac1 and/or Cdc42 in various types of cells, including glioma cells. Using a fluorescence resonance energy transfer-based A-kinase activity reporter (AKAR1), it has been found that gradients of PKA activity form with the strongest activity at the leading edge and are restricted to the basal surface in migrating cells. 19 Although an inverse association was seen between PKA activity and growth of U87MG glioma cells treated with caffeine, 25 constitutive expression of microsomal prostaglandin E synthase-1 (mPGES-1) is associated with increases in prostaglandin E2 (PGE2) production and U87MG cell growth when compared with astrocytes. PGE2 elevates cyclic AMP levels and activates PKA in U87MG cells. 26 When combined with agents that stimulate the cAMP/PKA pathway, gastrinreleasing peptide (GRP) promotes cell proliferation of U138MG glioma cells. 27 b 1 Pix, a p21-activated kinase (Pak)-interacting exchange factor, is a GEF that activates Rac1 and Cdc42 and thereby promotes cell motility. 8 PKA-dependent phosphorylation of serine 516 (S516) and threonine 526 (T526) residues regulates b 1 Pix translocation to focal adhesion 28 and mediates 14-3-3 binding to b 1 Pix, resulting in a conformation change that interferes with GTP binding to the GEF. 16 Importantly, various growth factors, including EGF, stimulate cell motility through PKAdependent activation of Rac1 or Cdc42 signaling. 15, 29 Consistent with this, we show that the PKA inhibitors H-89 and KT5720, a dominant negative PKI and ectopic expression of Dock180 S1250L mutant all inhibited EGFRvIII-stimulated cellular signaling, Rac1 activity, cell migration in vitro as well as in vivo brain tumor growth and invasion in mice. These results further support the notion that PKA-dependent protein phosphorylation of GEFs is critical for the growth and invasion of human cancers, including malignant gliomas. In addition to the induced protein phosphorylation of other GEFs, 8 serine/threonine phosphorylation of Dock180 was first described in integrin-stimulated NIH3T3 cells and transformed 3Y1 cells. The induced p-Dock180 was found to positively regulate signaling from integrins to Cas in these cells. 14 However, the identity of the phosphorylated AA residue(s) in the Dock180 protein was not determined. Our results provide the first and direct evidence of PKA-induced serine phosphorylation at AA residue S1250 of Dock180, and that such phosphorylation is required for EGFRvIII-stimulation of glioma cell invasion and tumorigenesis. The clinical relevance of these results is further highlighted by our finding that this particular S1250 residue of Dock180 was found to be mutated to L1250 in a clinical glioblastoma sample from a patient after treatment with temozolomide, a first line chemotherapeutic agent for clinical glioma treatment (TCGA_GBM_Level3_All_Somatic_Mutations, TCGA portal, https://tcga-data.nci.nih.gov). Although our data does not provide direct evidence that temozolomide induces S1250L mutation in glioma cells, our findings do offer mechanistic insights and functional validation of the effects of impaired phosphorylation of Dock180 S1250 on EGFRvIII-driven glioma tumorigenesis and invasion in vitro and in vivo.
Further, the induced p-Dock180 S1250 conceivably has a functional impact for Dock180 signaling, as S1250 is located in the DHR-2 domain of Dock180 that is required for GTP-GDP exchange during Rac1 activation through direct binding to Rac1. 10 Thus, a plausible mechanism is that the PKA-dependent p-Dock180 S1250 is required for Rac1 binding. This could be similar to the impact of Dock180 ISP , a mutant of Dock180 DHR-2 domain that abrogates Rac1 binding (Figure 4e) . 30 Another possible mechanism could be that the PKA-dependent p-Dock180 S1250 is important for Dock180 to acquire or maintain an active conformation. In this regard, it has been postulated that the Dock180 protein itself forms an inhibitory conformation with the SH3 domain at its N terminus folding back and covering the DHR-2 domain, thereby preventing GTP-loaded Rac1 from accessing the domain. Although it has been shown that ELMO1, the bipartite partner of Dock180, binds to the N terminus of Dock180 at the SH3 domain and opens the DHR-2 domain to Rac1. 10 The induced p-Dock180 S1250 could further facilitate the interaction of Rac1 to the DHR-2 domain of Dock180. This hypothetical scenario could be analogous to the activation of Vav1, a member of the GEF family. Vav1 is activated by Srcinduced phosphorylation of a tyrosine residue at its N terminus, opening its auto-inhibitory conformation and subsequently activating Rac1. 8 However, this hypothesis warrants further investigation.
Finally, we have recently reported that Src-dependent tyrosine phosphorylation of Dock180 mediated PDGFRa-and EGFRvIIIdriven glioma tumorigenesis and invasion in humans and in mice. 12, 13 In these studies, we showed that PDGFRa and EGFRvIII induce tyrosine phosphorylation of Dock180 at distinct tyrosine residues through Src or Src family kinase-dependent activation, and that such induced protein phosphorylation was required for PDGFRa-and EGFRvIII-stimulated glioma tumorigenesis and invasion in vitro and in vivo. Importantly, the PDGFRa-induced Y1181 of Dock180 was found in multiple types of clinical human cancers including gliomas. 12, 13 These results, together with those in the present study, demonstrate that protein phosphorylation of Dock180 either through Src-dependent tyrosine phosphorylation or PKA-induced serine phosphorylation is important for oncogenic signal-driven glioma tumorigenesis. These results also add to our knowledge that modulations of GEFs such as Dock180 mediate extracellular stimulation of cell motility and growth. 8 In summary, in this study, we demonstrate that PKA induction of p-Dock180 S1250 mediates EGFRvIII stimulation of glioma tumorigenesis and invasion in vitro and in vivo. We describe a novel mechanism by which EGFRvIII promotes glioma tumorigenicity through PKA-Dock180-Rac1 signaling. These results, together with our recent reports, 12, 13 further emphasize that post-translational modifications, namely protein phosphorylation of Dock180 is important for the activation of Rac1-mediated pathways by oncogenic EGFRvIII-or PDGFRa-signaling in gliomas. These studies suggest that therapeutic targeting of the induced p-Dock180-Rac1 pathway might be beneficial for developing effective treatments for patients with malignant gliomas and other types of human cancers.
MATERIALS AND METHODS
Cell lines
Human HEK293T (from ATCC, Manassas, VA, USA), LN444, SNB19 cells and primary human GBM cells were maintained and cultured as previously described. 12, 13, 22, 23, 31, 32 SNB19 and LN444 cell lines were gifts from Dr Y-H Zhou at University of California, Irvine, CA, USA, and Dr E van Meir at Emory University, Atlanta, GA, USA, respectively. SNB19 and LN444 cell lines were also recently authenticated using short tandem repeat DNA fingerprinting by RADIL (Columbia, MO, USA). Cell transfections were performed as previously described.
13 LN444/EGFRvIII and SNB19/EGFRvIII cell lines that overexpress exogenous EGFRvIII were established and characterized as previously described. 13 
Antibodies and reagents
The following antibodies were used in this study: anti-Dock180 (H-4) and anti-b-actin (I-19) antibodies (Santa Cruz Biotechnology, Dallas, TX, USA); an anti-Rac1 antibody (BD Transduction Laboratories, San Jose, CA, USA); a monoclonal anti-Flag M2 antibody (Sigma-Aldrich, St Louis, MO, USA); antiphospho-p44/42 MAP Kinase (Thr202/Tyr204, #9101), anti-p44/42 MAP Kinase (#9102), anti-phospho-Akt (Ser473, #4051), anti-Akt (#9272), and anti-phospho-EGFR (Tyr1045, #2237) antibodies (Cell Signaling Technology, Danvers, MA, USA); an anti-Ki-67 antigen (NCL-Ki67p) antibody (Leica Microsystems Inc, Buffalo Grove, IL, USA); anti-PKA antibody and anti-panphosphoserine (19/pSer) antibody (BD Transduction Laboratories). Rac1 activation was assessed using a commercially available assay kit (MilliporeUpstate, Billerica, CA, USA). The secondary antibodies were from Vector Laboratories (Burlingame, CA, USA) or Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Peroxidase blocking reagent was from DAKO (Carpinteria, CA, USA); AquaBlock was from East Coast Biologics, Inc. (North Berwick, ME, USA). Various inhibitors were used in this study: Erlotinib (LC Laboratories, Woburn, MA, USA), GF109203X (Enzo Life Science, Farmingdale, NY, USA); and PD-98059, Roscovitine, H-89, KT5720, and KN-93 (Sigma). Cell culture media and other reagents were from Invitrogen (San Diego, CA, USA), Sigma-Aldrich or ThermoFisher Scientific (Waltham, MA, USA).
Plasmids
The pcDNA3-Flag-Dock180, pLVX-Flag-Dock180, mutant Del-1, Del-2 and pcDNA3-(His) 6 -Dock180 plasmids were constructed as previously described.
12,13 A pcDNA3-EGFP-Rac1-WT (plasmid 12980) 33 was purchased from Addgene Inc. (Cambridge, MA, USA). Dock180 S1198L , Dock180 S1250L and Dock180 S1627L point mutations were generated using a Site-directed Mutagenesis Kit (Invitrogen) by following the manufacturer's protocol. A GFP-PKA inhibitor (GFP-PKI) was from Dr R Tsien at University of California, San Diego, CA, USA. 21 Immunoprecipitation, immunoblotting, cell proliferation and migration assays, and Rac1 activation assays IB and IP analyses were performed as we previously described. 12, 13 In vitro cell proliferation analyses were performed using a WST-1 assay kit (Roche, Indianapolis, IN, USA), cell viability assays were performed using a TUNEL assay kit (Roche), and cell migration and Rac1 activation assays were performed as we previously described. 12, 13 Tumorigenesis studies All experiments using animals were performed in accordance to a protocol approved by The University of Pittsburgh Institutional Animal Care and Use Committee (IACUC). Athymic (Ncr nu/nu) female mice at an age of 6-8 weeks (Taconic Farms, Hudson, NY, USA) were used for all animal experiments. Various human glioma cells (5 Â 10 5 in 5 ml PBS) were stereotactically implanted into the brain of individual mice with five mice per group. The glioma-bearing mice were killed between 7 and 8 weeks PKA-dependent serine phosphorylation of Dock180 H Feng et al
